|
|
|
| Curative effect observation of Climen combined with Escitalopram in the treatment of perimenopausal depression |
| ZHANG Zhi-hua1 WEN Ya-lan2 LUO Hong-yu3 |
1.Department of Obstetrics and Gynecology, Ganzhou Third People′s Hospital in Jiangxi Province, Ganzhou 341000,China;
2.Department of Gynecology and Obstetrics, Ganzhou Hospital of Traditional Chinese Medicine in Jiangxi Province, Ganzhou 341000, China;
3.Department of Obstetrics and Gynecology, Ganzhou Maternal and Child Health Hospital in Jiangxi Province, Ganzhou 341000, China |
|
|
|
|
Abstract Objective To explore the application of Estradiol Valproate Tablets/Escitalopram Tablets and Escitalopram in the treatment of perimenopausal depression. Methods A total of 60 patients with perimenopausal depression in Ganzhou Third People′s Hospital from January 2016 to December 2017 were selected as the subjects of the study.According to the random number table method, the patients were divided into the study group (30 cases) and the control group (30 cases).The study group was treated with Estradiol Valproate Tablets/Escitalopram Tablets + Escitalopram Tablets, while the control group was treated with Escitalopram.The Hamilton depression scale (HAMD), therapeutic effect and adverse reactions were compared between the two groups. Results The HAMD scores of the study group at the 4th, 8th and 12th weeks after treatment were lower than those of the control group, the differences were statistically significant (P＜0.05).The total effective rate of the study group was higher than that of the control group, the difference was statistically significant (P＜0.05).The total incidence of adverse reactions in the study group was lower than that in the control group, the difference was statistically significant (P＜0.05). Conclusion Estradiol Valerate Tablets/Escitalopram Tablets combined with Escitalopram are effective in the treatment of permenopausal depression, which can reduce the depression status of patients, improve the therapeutic effect, and have a lower incidence of adverse reactions.
|
|
|
|
|
|
| [1] |
黄宏丽，沈捷雯，董亚兰，等.针药并用对围绝经期抑郁症患者HAMD 积分、SDS 积分及HPO 轴的影响[J].上海针灸杂志，2017，36（6）：705-710.
|
| [2] |
李月娥，徐上知，吕淑云，等.维吾尔族、汉族围绝经期抑郁症患者女性激素水平和社会心理因素的对比[J].中国妇幼保健，2015，30（35）：6333-6336.
|
| [3] |
崔鹤，娄小平.自我管理对围绝经期抑郁症患者抑郁状态及生存质量的影响[J].河南医学研究，2016，25（8）：1527-1528.
|
| [4] |
张家秀，韩利，瞿娜.雌激素受体α 在围绝经期女性抑郁症发病中的作用及机制[J].中国妇幼保健，2015，30（15）：2327-2328.
|
| [5] |
赵宁，雷勇，贾卫静，等.小剂量激素治疗对围绝经期女性生活质量和激素水平的影响[J].河北医药，2016，38（18）：2808-2810.
|
| [6] |
陈军良，骆建忠，姜诚勇，等.围绝经期妇女抑郁症发生情况及相关因素分析[J].中国慢性病预防与控制，2014，22（6）：672-674.
|
| [7] |
王相兰，陶炯，钟智勇，等.围绝经期女性静息状态下丘脑功能连接与性激素和抑郁症状的相关性[J].中华医学杂志，2015，95（39）：3190-3195.
|
| [8] |
Li S，Li ZF，Wu Q，et al.A Multicenter，randomized，controlled trial of electroacupuncture for perimenopause women with mild-moderate depression[J].BMRI，2018，2018（4）：1-7.
|
| [9] |
Michael C.HRT should be considered as first line therapy for perimenopausal depression：AGAINST：more clinical trials are needed[J].BJOG，2016，123（6）：1011-1011.
|
| [10] |
蔡胤浩，张亚华，范良敏.老年2 型糖尿病合并抑郁症患者炎症因子及胰岛素抵抗与抑郁严重程度的关系[J].中国老年学杂志，2015，35（22）：6577-6578.
|
| [11] |
陈宁贵，廖敏.解郁丸联合西酞普兰治疗难治性抑郁症的疗效及其对血清去甲肾上腺素和5-羟色胺及脑源性神经营养因子指标的影响研究[J].中国全科医学，2017，20（S2）：338-340.
|
| [12] |
司天梅，陈胜良，郝伟，等.5-HT1A受体参与常见精神疾病病理机制及5-HT1A受体部分激动剂的潜在治疗效应研究进展[J].中国新药与临床杂志，2018，37（9）：8-13.
|
| [13] |
况雷雨，谷传正，吉峰.阿戈美拉汀与5-HT 再摄取抑制剂治疗抑郁症安全性的meta 分析[J].中华行为医学与脑科学杂志，2016，25（6）：565-571.
|
| [14] |
白树新，李莉，王德斌，等.草酸艾司西酞普兰联合化瘀理气清热汤治疗脑卒中后抑郁疗效及对血清DA、5-HT及NE 含量的影响[J].现代中西医结合杂志，2017，26（15）：1644-1646.
|
| [15] |
刘岱岳，钟明洁，任敏清，等.雌激素联合抗抑郁药物治疗我国围绝经期妇女抑郁效果评价的Meta 分析[J].重庆医学，2017，46（24）：3370-3374.
|
|
|
|
